UniDoc Announces Amended LIFE Offering
UniDoc Health Corp (OTC:UDOCF) amended its previously announced non-brokered private placement LIFE offering to include a minimum raise of $800,000 and retain a maximum of $1,500,000.
The Offering now covers a minimum of 5,333,333 Units and up to 10,000,000 Units at $0.15 per Unit. Each Unit includes one common share and one transferable warrant exercisable at $0.25 for 36 months. Proceeds are designated for inventory, marketing and investor relations, working capital, and general corporate purposes.
The Offering uses the listed issuer financing exemption under NI 45-106 (ex-Quebec), the securities for Canadian resident subscribers will not be subject to resale restrictions, and closing is expected on or about October 22, 2025 (or within 45 days of October 17, 2025), subject to customary approvals including the CSE.
UniDoc Health Corp (OTC:UDOCF) ha modificato la sua offerta privata non brokerata LIFE annunciata in precedenza per includere un importo minimo da raccogliere di 800.000 dollari e mantenere un massimo di 1.500.000 dollari.
L'offerta ora copre un minimo di 5.333.333 Unità e fino a 10.000.000 di Unità a 0,15 $ per unità. Ogni unità include una azione ordinaria e un warrant trasferibile exercibile a 0,25 $ per 36 mesi. I proventi sono destinati a inventario, marketing e relazioni con gli investitori, capitale circolante e scopi aziendali generali.
L'Offerta utilizza l'eccezione di finanziamento per emittenti quotati ai sensi del NI 45-106 (ex-Quebec); i titoli per i sottoscrittori residenti in Canada non saranno soggetti a restrizioni di rivendita e la chiusura è prevista intorno al 22 ottobre 2025 (o entro 45 giorni dal 17 ottobre 2025), soggetta alle consuete approvazioni tra cui la CSE.
UniDoc Health Corp (OTC:UDOCF) enmendó su oferta privada no brokered LIFE previamente anunciada para incluir un importe mínimo de $800,000 y mantener un máximo de $1,500,000.
La oferta ahora cubre un mínimo de 5,333,333 unidades y hasta 10,000,000 unidades a $0.15 por unidad. Cada unidad incluye una acción común y una garantía transferible exercitable a $0.25 por 36 meses. Los fondos se destinarán para inventario, marketing y relaciones con inversores, capital de trabajo y fines corporativos generales.
La oferta utiliza la exención de financiación del emisor listado bajo NI 45-106 (ex-Quebec); los valores para suscriptores residentes canadienses no estarán sujetos a restricciones de reventa, y se espera el cierre alrededor del 22 de octubre de 2025 (o dentro de 45 días desde el 17 de octubre de 2025), sujeto a aprobaciones habituales incluyendo la CSE.
유니닥 헬스 주식회사(OTC:UDOCF)는 이전에 발표된 비중개(private) 비공개 공급 LIFE 제안을 최소 80만 달러의 조달 금액을 포함하고 최대 150만 달러로 유지되도록 수정했습니다.
제안은 이제 최소 5,333,333 유닛 및 최대 10,000,000 유닛으로 구성되며 유닛당 $0.15에 판매됩니다. 각 유닛은 보통주 1주와 $0.25에 행사 가능한 양도 가능한 워런트를 포함하며 36개월의 기간 동안 행사 가능합니다. 수익은 재고, 마케팅 및 투자자 관계, 운전자본 및 일반 기업 목적에 배정됩니다.
공급은 NI 45-106에 따른 상장기업 파이낸싱 면제를 사용하며(퀘벡 제외), 캐나다 거주 구독자의 증권은 재매각 제한의 대상이 되지 않으며 종료는 대략 2025년 10월 22일 경에 예상되며(또는 2025년 10월 17일로부터 45일 이내), CSE를 포함한 관례적 승인에 따라 달라질 수 있습니다.
UniDoc Health Corp (OTC:UDOCF) a modifié son offre privée non intermédiée LIFE anunciée précédemment pour inclure une levée minimale de 800 000 $ et maintenir un maximum de 1 500 000 $.
L’offre couvre désormais un minimum de 5 333 333 unités et jusqu’à 10 000 000 d’unités à 0,15 $US par unité. Chaque unité comprend une action ordinaire et un warrant transférable exercitable à 0,25 $ pendant 36 mois. Les fonds seront destinés à l’inventaire, au marketing et aux relations avec les investisseurs, au fonds de roulement et à des fins générales d’entreprise.
L’offre utilise l’exemption de financement des émetteurs cotés sous NI 45-106 (anciennement Québec); les titres pour les souscripteurs résidents canadiens ne seront pas soumis à des restrictions de revente, et la clôture est prévue le ou autour du 22 octobre 2025 (ou dans les 45 jours suivant le 17 octobre 2025), sous réserve des approbations habituelles y compris le CSE.
UniDoc Health Corp (OTC:UDOCF) hat sein zuvor angekündigtes, nicht brokered Private Placement LIFE-Angebot geändert, um eine Mindestzeichnung von 800.000 $ zu berücksichtigen und eine Höchstzeichnung von 1.500.000 $ beizubehalten.
Das Angebot deckt nun mindestens 5.333.333 Einheiten und bis zu 10.000.000 Einheiten zu 0,15 $ pro Einheit ab. Jede Einheit umfasst eine Stammaktie und eine übertragbare Warranthülle, die zu 0,25 $ für 36 Monate ausübbar ist. Die Erlöse sind vorgesehen für Inventar, Marketing und Investor Relations, Working Capital und allgemeine Unternehmenszwecke.
Das Angebot nutzt die gelistete Emittenten-Finanzierungsausnahme gemäß NI 45-106 (ehemals Québec); die Wertpapiere für kanadische inländische Abonnenten unterliegen nicht Wiederverkaufsbeschränkungen, und der Abschluss wird voraussichtlich am oder um den 22. Oktober 2025 erfolgen (oder innerhalb von 45 Tagen nach dem 17. Oktober 2025), vorbehaltlich üblicher Genehmigungen einschließlich CSE.
شركة UniDoc Health (OTC:UDOCF) عدّلت عرضها الخاص غير الوسيط LIFE الذي أُعلن عنه سابقاً ليشمل جمعاً لا يقل عن 800,000 دولار ويحتفظ بـحد أقصى 1,500,000 دولار.
يغطّي العرض الآن حدّاً أدنى من 5,333,333 وحدة وحتى 10,000,000 وحدة بسعر $0.15 لكل وحدة. تتضمن كل وحدة سهماً عادياً واحداً و
يستخدم العرض استثناء تمويل المصدر المدرج بموجب NI 45-106 (سابقاً كيبيك)، ولن تكون الأوراق المالية للمشتركين المقيمين في كندا خاضعة لقيود إعادة البيع، ومن المتوقع الإغلاق في أو حول 22 أكتوبر 2025 (أو خلال 45 يوماً من 17 أكتوبر 2025)، رهن بالموافقات المعتادة بما في ذلك CSE.
UniDoc Health Corp (OTC:UDOCF) 修改了其先前宣布的非经纪私募发行 LIFE，改为包含一个最低筹资额80万美元和保持一个最高150万美元。
该发行现在覆盖最少5,333,333份单位，最多10,000,000份单位，单位价格为$0.15。每份单位包含一股普通股和一个可转让、可在36个月内以$0.25行使的认股权证。募集资金用于库存、市场营销与投资者关系、运营资金及一般企业用途。
该发行在NI 45-106（前魁北克）下使用上市发行人融资豁免，面向加拿大居民的认购人证券将不受转售限制，预计于大约2025年10月22日或在2025年10月17日后45天内完成，须经包括CSE在内的惯常审批。
- Minimum gross proceeds of $800,000 secured by amended terms
- Maximum offering size preserved at $1,500,000
- Each Unit includes a $0.25 warrant exercisable for 36 months
- Proceeds allocated to inventory, marketing, working capital
- Up to 10,000,000 Units may dilute existing shareholders
- Warrant exercise could add dilution if holders exercise at $0.25
- Closing subject to CSE approval and customary conditions
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T) ("UniDoc" or the "Company") is pleased to announce that further to its previously announced non-brokered private placement LIFE offering (the "Offering") for total gross proceeds of up to
The Offering will now consist of a minimum of 5,333,333 Units for minimum gross proceeds of
As previously disclosed, the Company plans to use the proceeds from the Offering for inventory, marketing and investor relations services, working capital, and general corporate purposes.
The Units will be offered by way of the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106") in all of the provinces and territories of Canada excluding Quebec. Pursuant to NI 45-106, the securities forming part of the Units issued to Canadian resident subscribers under the Offering will not be subject to resale restrictions.
An amended and restated offering document (the "Amended Offering Document") related to the Offering will be made available under the Company's profile on SEDAR+ at www.sedarplus.com. The Amended Offering Document will also be made available on the issuer's website at www.unidoctor.com. Prospective investors of the Units should read the Amended Offering Document before making an investment decision.
The Offering is expected to close on or about October 22, 2025, or such other date that is within 45 days from October 17, 2025, as the Company may agree. The Offering remains subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the CSE.
On Behalf of the Board of Directors,
~Antonio Baldassarre~
Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.
About UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF)
UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician's office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company's belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.
For further information, please contact:
UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com
Matt Chatterton, Director Tel: +1 778.613.2082
Email: matt@unidoctor.com
Media Inquiries media@unidoctor.com
Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to: the Offering, completion of the Offering, the expected closing date of the Offering, and the use of proceeds of the Offering. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "anticipates", "anticipated" "expected" "intends" "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are from those expressed or implied by such forward-looking statements or forward-looking information subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different, including receipt of all necessary regulatory approvals. Although management of the Company have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: UniDoc Health Corp.
View the original press release on ACCESS Newswire
FAQ
What are the amended terms of UniDoc's LIFE offering (UDOCF) on October 17, 2025?
When is the UDOCF offering expected to close and what approval is required?
How will UniDoc (UDOCF) use proceeds from the LIFE offering?
What is the warrant structure in UniDoc's amended offering (UDOCF)?
Are securities from UniDoc's offering (UDOCF) subject to resale restrictions in Canada?
How many shares could be issued under UniDoc's maximum offering (UDOCF)?
